-+ 0.00%
-+ 0.00%
-+ 0.00%

Hoth Therapeutics Releases Preclinical Safety Data For Cancer Fighting HT-KIT Including 100% Clean Safety Profile And No Adverse Effects On Kidney, Spleen, Or Thymus

Benzinga·06/18/2025 12:24:32
Listen to the news

HOTH ALERT: Hoth Therapeutics Reports Positive Preclinical Safety Data for HT-KIT — Dose-Dependent Activity, No Toxicity, IND on Deck

HOTH announces strong preclinical data for HT-KIT showing dose-dependent liver activity with zero observed toxicity – key milestone as the company prepares for IND filing.

Study Results:

  • Liver weight increased from 1.11g → 1.32g across 0 → 3.0 mg/kg
  • No adverse effects on kidney, spleen, or thymus
  • 100% clean safety profile — no visible lesions or gross pathology
  • Validates safety of HT-KIT in vivo

Robb Knie, CEO: "These results strengthen our confidence in HT-KIT as we advance toward clinical trials. A strong safety signal with dose responsiveness and no toxicity gives us a clear path forward."